Product Design and Synthesis Design of the optimal conjugate structure for each particular target drug.
Research Analysis Accurate in vitro and in vivo characterization of the therapeutic conjugates, including biological characterization (e.g., pharmacokinetic and immunologic studies).
Quality Control: Characterization and purification of polymer starting materials and activated polymers; process controls to ensure purity, reproducibility and regulatory compliance.
Next Generation Reagents for Optimized, Cost-Effective PEGylation:PharmaPEG® PuriPEG®
Process Development: Development and scale-up of processes for clinical trials and commercial manufacturing.
Partnerships have included collaborations with leading organizations such as the National Cancer Institute, Schering AG, Savient Pharmaceuticals, Inc., Debiopharm S.A., and Duke University.
If interested in working with a leader in bioconjugation and a leader in developing next generation products, please send a communication to busdev@mvpharm.com or contact us directly at (650) 365-5515.